The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumors, targeted sequencing of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) may help differential diagnosis when surgery is not recommended and be more representative of tumor heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient follow-up. Confounding factors may be represented by cfDNA variations due to concomitant pathologies (inflammatory diseases, seizures) or clonal hematopoiesis. Pilot studies suggest that methylome analysis of cfDNA from plasma and temporary opening of the blood-brain barrier by ultrasounds have the potential to overcome some of these limitations. Together with this, an increased understanding of mechanisms modulating the shedding of cfDNA by the tumor may help to decrypt the meaning of cfDNA kinetics in blood or CSF.

The coming of age of liquid biopsy in neuro-oncology / Berzero, G; Pieri, V; Mortini, P; Filippi, M; Finocchiaro, G. - In: BRAIN. - ISSN 0006-8950. - 146:10(2023), pp. 4015-4024. [10.1093/brain/awad195]

The coming of age of liquid biopsy in neuro-oncology

Berzero G
Co-primo
;
Pieri V
Co-primo
;
Mortini P
Secondo
;
Filippi M
Penultimo
;
2023-01-01

Abstract

The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumors, targeted sequencing of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) may help differential diagnosis when surgery is not recommended and be more representative of tumor heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient follow-up. Confounding factors may be represented by cfDNA variations due to concomitant pathologies (inflammatory diseases, seizures) or clonal hematopoiesis. Pilot studies suggest that methylome analysis of cfDNA from plasma and temporary opening of the blood-brain barrier by ultrasounds have the potential to overcome some of these limitations. Together with this, an increased understanding of mechanisms modulating the shedding of cfDNA by the tumor may help to decrypt the meaning of cfDNA kinetics in blood or CSF.
2023
liquid biopsy, brain tumors, cell-free DNA, methylome, targeted sequencing
File in questo prodotto:
File Dimensione Formato  
Brain 146_4015.pdf

accesso aperto

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Creative commons
Dimensione 694.19 kB
Formato Adobe PDF
694.19 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/143118
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 3
social impact